Caredx Inc
Research Caredx Inc (CDNA) on Bullrun: market cap USD 3.28B, P/E 30.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCDNA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryDiagnostics & Research
- CurrencyUSD
- Market capUSD 3.28B
- P/E30.7
- Financial periodQ2 2026
- RevenueUSD 131.95M
- Net incomeUSD 110.64M
- Free cash flowUSD 28.75M
- Gross margin73.5%
Valuation Snapshot
latest market cap is USD 3.28B; P/E is 30.7.
Peer valuation comparison
Latest P/E is 30.69x versus a Healthcare sector median of 24.64x (24.5% above).
Latest P/E is 30.69x versus a United States median of 23.85x (28.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 379.81M | -USD 21.35M | USD 35.44M | 67.6% | -0.4 | USD 65.43M | USD 26.19M | USD 303.10M |
| FY2024 | USD 333.79M | USD 52.55M | USD 31.56M | 67.1% | 0.93 | USD 114.69M | USD 28.37M | USD 378.43M |
| FY2023 | USD 280.32M | -USD 190.28M | -USD 27.63M | 63.6% | -3.54 | USD 82.20M | USD 34.22M | USD 261.33M |
| FY2022 | USD 321.79M | -USD 76.61M | -USD 49.57M | 65.1% | -1.44 | USD 89.92M | USD 39.00M | USD 430.91M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 3.28B | 30.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 959.27M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.17B | 25.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 649.18M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 610.86M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.41B | n/a | n/a | n/a |
About Caredx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
ETFs that hold Caredx Inc
Caredx Inc is one of the ten largest holdings of 2 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| ARK Genomic | 5.15% | 0.75% |
| L&G Healthcare Technology & Innovation ETF USD Acc | 2.76% | 0.49% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Caredx Inc's market cap?
Caredx Inc's market capitalization is USD 3.28B.
What is Caredx Inc's P/E ratio?
Caredx Inc's price-to-earnings (P/E) ratio is 30.7.
What does Caredx Inc do?
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.